title: Phase II study of neo-adjuvant gemcitabine plus epirubicin in primarily unresectable locally advanced breast cancer.
authors.forename: Juan Alejandro
authors.initials: JA
authors.lastname: Silva
authors.forename: Mario
authors.initials: M
authors.lastname: Pérez
authors.forename: Samuel
authors.initials: S
authors.lastname: Rivera
authors.forename: Guillermo
authors.initials: G
authors.lastname: Olivares
authors.forename: Victor
authors.initials: V
authors.lastname: Lira-Puerto
authors.forename: Noel
authors.initials: N
authors.lastname: Castañeda
authors.forename: Flavia
authors.initials: F
authors.lastname: Morales
authors.forename: Germán
authors.initials: G
authors.lastname: Calderillo
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Alcedo
authors.forename: F
authors.initials: F
authors.lastname: Oñate-Ocaña
authors.forename: Dolores
authors.initials: D
authors.lastname: Gallardo
authors.forename: Jaime
authors.initials: J
authors.lastname: De La Garza
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine